INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 146 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $102 | +142.9% | 5,510 | +46.0% | 0.00% | – |
Q2 2023 | $42 | -8.7% | 3,774 | +9.7% | 0.00% | – |
Q1 2023 | $46 | -6.1% | 3,439 | -13.0% | 0.00% | – |
Q4 2022 | $49 | -99.9% | 3,951 | 0.0% | 0.00% | -100.0% |
Q3 2022 | $55,000 | +1.9% | 3,951 | +1.5% | 0.00% | 0.0% |
Q2 2022 | $54,000 | -18.2% | 3,891 | -4.6% | 0.00% | 0.0% |
Q1 2022 | $66,000 | -76.8% | 4,078 | -9.6% | 0.00% | -85.7% |
Q1 2020 | $284,000 | -51.3% | 4,512 | -4.0% | 0.01% | -36.4% |
Q4 2019 | $583,000 | +100.3% | 4,701 | +7.3% | 0.01% | +83.3% |
Q3 2019 | $291,000 | -17.8% | 4,382 | -1.4% | 0.01% | -25.0% |
Q2 2019 | $354,000 | -4.8% | 4,445 | +33.6% | 0.01% | -11.1% |
Q1 2019 | $372,000 | +15.5% | 3,328 | +4.1% | 0.01% | 0.0% |
Q4 2018 | $322,000 | +15.0% | 3,196 | -4.2% | 0.01% | +28.6% |
Q2 2018 | $280,000 | +18.6% | 3,337 | -12.9% | 0.01% | +16.7% |
Q1 2018 | $236,000 | +12.9% | 3,831 | +6.9% | 0.01% | 0.0% |
Q4 2017 | $209,000 | -46.5% | 3,584 | +11.1% | 0.01% | -53.8% |
Q2 2017 | $391,000 | +44.3% | 3,226 | +34.6% | 0.01% | 0.0% |
Q1 2017 | $271,000 | -14.8% | 2,396 | -18.1% | 0.01% | -7.1% |
Q4 2016 | $318,000 | -26.2% | 2,927 | +11.7% | 0.01% | -44.0% |
Q3 2016 | $431,000 | +4.4% | 2,620 | +0.0% | 0.02% | +4.2% |
Q2 2016 | $413,000 | +70.7% | 2,619 | +39.0% | 0.02% | 0.0% |
Q1 2016 | $242,000 | -6.9% | 1,884 | +8.4% | 0.02% | -25.0% |
Q4 2015 | $260,000 | -15.9% | 1,738 | -6.6% | 0.03% | 0.0% |
Q3 2015 | $309,000 | -30.2% | 1,861 | +1.3% | 0.03% | -27.3% |
Q2 2015 | $443,000 | +5.0% | 1,837 | +22.6% | 0.04% | -15.4% |
Q1 2015 | $422,000 | +99.1% | 1,498 | +10.1% | 0.05% | +57.6% |
Q4 2014 | $212,000 | -33.8% | 1,361 | +0.5% | 0.03% | -31.2% |
Q3 2014 | $320,000 | +0.6% | 1,354 | +0.8% | 0.05% | 0.0% |
Q2 2014 | $318,000 | +30.9% | 1,343 | +82.2% | 0.05% | +14.3% |
Q1 2014 | $243,000 | – | 737 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |